Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

Total Liabilities Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual total liabilities in 2023 was 3.71 Million EUR , down -26.53% from previous year.
  • Neovacs S.A.'s latest quarterly total liabilities in 2024 Q2 was 25.28 Million EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported annual total liabilities of 5.05 Million EUR in 2022, up 8.62% from previous year.
  • Neovacs S.A. reported annual total liabilities of 4.65 Million EUR in 2021, up 85.71% from previous year.
  • Neovacs S.A. reported quarterly total liabilities of 3.71 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • Neovacs S.A. reported quarterly total liabilities of 3.71 Million EUR for 2023 FY, down -26.53% from previous quarter.

Annual Total Liabilities Chart of Neovacs S.A. (2023 - 2009)

Historical Annual Total Liabilities of Neovacs S.A. (2023 - 2009)

Year Total Liabilities Total Liabilities Growth
2023 3.71 Million EUR -26.53%
2022 5.05 Million EUR 8.62%
2021 4.65 Million EUR 85.71%
2020 2.5 Million EUR -47.81%
2019 4.79 Million EUR -0.06%
2018 4.8 Million EUR -55.64%
2017 10.82 Million EUR 33.98%
2016 8.07 Million EUR 55.84%
2015 5.18 Million EUR 48.65%
2014 3.48 Million EUR -52.12%
2013 7.28 Million EUR 38.18%
2012 5.27 Million EUR 118.34%
2011 2.41 Million EUR 0.39%
2010 2.4 Million EUR -50.69%
2009 4.87 Million EUR 0.0%

Peer Total Liabilities Comparison of Neovacs S.A.

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR 46.295%
ABIVAX Société Anonyme 131.05 Million EUR 97.167%
Adocia SA 31.87 Million EUR 88.352%
Aelis Farma SA 13.08 Million EUR 71.62%
Biophytis S.A. 15.84 Million EUR 76.578%
Advicenne S.A. 24.37 Million EUR 84.772%
genOway Société anonyme 14.45 Million EUR 74.327%
IntegraGen SA 5.97 Million EUR 37.922%
Medesis Pharma S.A. 6.42 Million EUR 42.234%
NFL Biosciences SA 3.62 Million EUR -2.526%
Plant Advanced Technologies SA 6.78 Million EUR 45.268%
Quantum Genomics Société Anonyme 3.31 Million EUR -12.145%
Sensorion SA 13.22 Million EUR 71.936%
Theranexus Société Anonyme 5.01 Million EUR 25.997%
TME Pharma N.V. 2.78 Million EUR -33.29%
Valbiotis SA 13.7 Million EUR 72.92%
TheraVet SA 1.48 Million EUR -149.976%
Valerio Therapeutics Société anonyme 20.46 Million EUR 81.864%
argenx SE 402.79 Million EUR 99.078%
BioSenic S.A. 32.26 Million EUR 88.495%
Celyad Oncology SA 9.97 Million EUR 62.797%
DBV Technologies S.A. 38.74 Million USD 90.419%
Galapagos NV 1.56 Billion EUR 99.762%
Genfit S.A. 105.92 Million EUR 96.495%
GeNeuro SA 20.13 Million EUR 81.568%
Hyloris Pharmaceuticals SA 8.61 Million EUR 56.896%
Innate Pharma S.A. 132.29 Million EUR 97.194%
Inventiva S.A. 101.59 Million EUR 96.346%
MaaT Pharma SA 22.46 Million EUR 83.476%
MedinCell S.A. 77.77 Million EUR 95.227%
Nanobiotix S.A. 95.74 Million EUR 96.123%
Onward Medical N.V. 25.69 Million EUR 85.555%
Oryzon Genomics S.A. 25.12 Million EUR 85.226%
OSE Immunotherapeutics SA 59.07 Million EUR 93.717%
Oxurion NV 19.73 Million EUR 81.191%
Pharming Group N.V. 228.28 Million EUR 98.374%
Poxel S.A. 53.9 Million EUR 93.113%
GenSight Biologics S.A. 34.72 Million EUR 89.311%
Transgene SA 26.51 Million EUR 86.001%
Financière de Tubize SA 123.65 Million EUR 96.998%
UCB SA 6.56 Billion EUR 99.943%
Valneva SE 341.14 Million EUR 98.912%
Vivoryon Therapeutics N.V. 4.54 Million EUR 18.361%